Gene Therapy for Sickle Cell Disease Likely Cost-Effective at
Incremental cost-effectiveness ratios were $126,000 and $281,000 per QALY for two simulation models from a societal perspective.
Incremental cost-effectiveness ratios were $126,000 and $281,000 per QALY for two simulation models from a societal perspective.
Aliya Khan, MD, at McMaster University, highlights the best practices to diagnose and treat tumor-induced osteomalacia (TIO)
The mission of the Smith-Magenis Research Foundation is to support research to improve the knowledge and understanding of Smith-Magenis Syndrome (SMS) so that viable therapeutic…
Brahm Goldstein, MD, Vice President, R&D, Hematology at CSL Behring, discusses HEMGENIX, a pivotal gene therapy for hemophilia B.
Wenyu Huang, MD, PhD highlights the latest clinical research about acromegaly, a rare endocrine disorder, presented at ENDO 2023.
We have noticed an unusual activity from your IP 199.16.157.183 and blocked access to this
Alaa Hamed, MD, Global Head of Medical Affairs Rare Diseases at Sanofi, discusses the importance of rare disease registries.
Roger A. Levy, MD, Senior Global Medical Director, GSK Specialty Medicine, discusses Lupus nephritis, a rare kidney disorder.
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
Wiley will announce that it will shutter 19 more journals, some tainted by fraud.
ELSTON, SHERRIE LYNN, was called home on October 9, 2005. She was 34 years old and had fought a long battle with ALS (Lou Gehrig’s…